Clinical Oncology Next Generation Sequencing Market Registering A CAGR Of 14.70% From 2021 To 2028
San Francisco, 27 April 2021: The Report Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow, By Technology (WGS, WES), By Application (Screening, Companion Diagnostics), By End-use, And Segment Forecasts, 2021 - 2028 The global clinical oncology next generation sequencing market size is expected to reach USD 892.61 million by 2028 registering a CAGR of 14.70%, according to a new report by Grand View Research, Inc. Technological advancements in next-generation sequencing coupled with high adoption of companion diagnostics and personalized medicine drive the global market growth. In addition, a rise in the utility of next generation sequencing (NGS) for liquid biopsy is expected to increase revenue generation in the market. NGS is employed to sequence circulating tumor DNA (ctDNA) for the analysis of liquid biopsy samples. This leads to efficient molecular profiling of tumors, which, in turn, facilitates real-time, non-invasive